Clinical trials: Therapy-related Toxicity
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
ALL, Childhood, Pediatric Cancer
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event
- Trial name
- MPGx-INDALL (NCT05512169)
- Where
- 2 sites in India
- Volunteers
- 556 people
- Sponsor
- University of Geneva, Switzerland
Hepatitis, Toxic
Cholestatic Drug-induced Liver Injury
Cholestatic drug-induced liver injury (DILI) is the severe form of DILI with a grave outcome. Drug-metabolizing enzymes play an important role in the metabolism of drugs.
- Trial name
- DILI (NCT01141322)
- Testing
- Ursodeoxycholic Acid
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Breast Neoplasms, Cardiotoxicity
The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.
This trial is to explore the optimal strategies for guaranteeing the cardiac safety of breast cancer patients following adjuvant radiotherapy in the modern era of multidisciplinary treatment.
- Trial name
- NCT02942615
- Testing
- limit heart dose
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Ruijin Hospital
Cancer, Fertility Issues
Impact of Gonadotoxic Therapies on Fertility
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.
- Conditions
- Cancer, Fertility Issues, Fertility Preservation, Toxicity Due to Chemotherapy
- Trial name
- FertiTOX (NCT05885048)
- Testing
- Blood samples for analysis, Sperm samples for analysis, Satisfaction evaluation
- Where
- Switzerland
- Volunteers
- 7,000 people
- Sponsor
- Michael von Wolff
Skin Toxicities
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment…
- Trial name
- FAST (NCT01015326)
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Visceral Leishmaniasis
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
The purpose of this study is to evaluate the effectiveness of treatment with PMIM in patients with visceral leishmaniasis within the VL-endemic region of Bangladesh at EOT (21/22 days after treatment begins), and at 6 months…
- Trial name
- NCT01328457
- Testing
- Paromomycin sulfate
- Where
- 3 sites in Bangladesh
- Volunteers
- 120 people
- Sponsor
- PATH
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Heart Failure, Breast Cancer
Cardiac Toxicity in Medical Treatment of Breast Cancer
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.
- Trial name
- CaTOB (NCT02440620)
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Odense University Hospital
Lymphoma
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- ManteauRiBVD (NCT00740415)
- Testing
- rituximab, bortezomib, dexamethasone
- Where
- France
- Volunteers
- 39 people
- Sponsor
- French Innovative Leukemia Organisation
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Advanced or Metastatic Solid Malignancy
Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities
Single center, non-randomized, interventional pilot study with feasibility analysis after enrollment of 20 patients. Adult patients with advanced solid tumors, for whom standard palliative treatment with targeted agents as…
- Trial name
- NCT01758575
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Cancer-related Problem/Condition, Head and Neck Cancer
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known.
- Conditions
- Cancer-related Problem/Condition, Head and Neck Cancer, Pain
- Trial name
- NCT00006994
- Testing
- glutamine, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- SWOG Cancer Research Network
Toxic Epidermal Necrolysis
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
- Trial name
- NCT00372723
- Testing
- Remicaide (infliximab)
- Sponsor
- Loyola University
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Non Small Cell Lung Cancer
Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.
There are preliminary data suggesting that patients suffering from non-insulin-dependent diabetes mellitus, treated with metformin, have improved local tumor control.
- Trial name
- Metformin (NCT02109549)
- Where
- 3 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht Radiation Oncology